Total Payments
$4,034
2024 Payments
$102.84
Companies
12
Transactions
20
Medicare Patients
1,038
Medicare Billing
$152,272
Payment Breakdown by Category
Consulting$2,400 (59.5%)
Travel$856.45 (21.2%)
Food & Beverage$777.76 (19.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,400 | 1 | 59.5% |
| Travel and Lodging | $856.45 | 2 | 21.2% |
| Food and Beverage | $777.76 | 17 | 19.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $3,501 | 4 | $0 (2018) |
| Novocure Inc. | $135.43 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $121.12 | 3 | $0 (2017) |
| Incyte Corporation | $102.84 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $56.09 | 3 | $0 (2017) |
| Celgene Corporation | $35.60 | 2 | $0 (2018) |
| Millennium Pharmaceuticals, Inc. | $15.72 | 1 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $15.12 | 1 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $14.29 | 1 | $0 (2017) |
| ARIAD Pharmaceuticals, Inc. | $13.76 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $102.84 | 1 | Incyte Corporation ($102.84) |
| 2018 | $3,525 | 5 | Genentech USA, Inc. ($3,501) |
| 2017 | $406.73 | 14 | Novocure Inc. ($135.43) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/17/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $102.84 | General |
| Category: Hematology/Oncology | ||||||
| 10/15/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: Oncology | ||||||
| 03/23/2018 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, VENCLEXTA | Food and Beverage | In-kind items and services | $244.79 | General |
| Category: BioOncology/Immunology | ||||||
| 03/22/2018 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, VENCLEXTA | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: BioOncology/Immunology | ||||||
| 03/22/2018 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, VENCLEXTA | Travel and Lodging | In-kind items and services | $585.25 | General |
| Category: BioOncology/Immunology | ||||||
| 03/22/2018 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, VENCLEXTA | Travel and Lodging | In-kind items and services | $271.20 | General |
| Category: BioOncology/Immunology | ||||||
| 10/17/2017 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $135.43 | General |
| Category: Oncology | ||||||
| 07/31/2017 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: HEMATOLOGY | ||||||
| 07/19/2017 | Bayer HealthCare Pharmaceuticals Inc. | Nexavar (Drug) | Food and Beverage | In-kind items and services | $12.26 | General |
| Category: Oncology | ||||||
| 07/13/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2017 | Janssen Scientific Affairs, LLC | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Oncology | ||||||
| 06/06/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $11.53 | General |
| Category: ONCOLOGY | ||||||
| 03/02/2017 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2017 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $10.74 | General |
| Category: Oncology | ||||||
| 02/09/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.29 | General |
| Category: Oncology | ||||||
| 02/08/2017 | ARIAD Pharmaceuticals, Inc. | Iclusig (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Not Applicable | ||||||
| 02/02/2017 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $12.20 | General |
| Category: Oncology | ||||||
| 01/25/2017 | Millennium Pharmaceuticals, Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Oncology | ||||||
| 01/12/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $92.15 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 333 | 526 | $208,032 | $47,147 |
| 2022 | 5 | 281 | 540 | $241,440 | $45,349 |
| 2021 | 5 | 191 | 312 | $146,810 | $28,388 |
| 2020 | 5 | 233 | 407 | $186,654 | $31,387 |
Total Patients
1,038
Total Services
1,785
Medicare Billing
$152,272
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 85 | 130 | $54,620 | $13,587 | 24.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 46 | 130 | $39,900 | $11,510 | 28.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 103 | 150 | $54,676 | $9,532 | 17.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 38 | $17,230 | $3,748 | 21.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 27 | $15,810 | $2,990 | 18.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $12,446 | $2,740 | 22.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $9,016 | $2,078 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 14 | $4,334 | $961.48 | 22.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 48 | 197 | $68,950 | $14,897 | 21.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 121 | 208 | $92,768 | $14,034 | 15.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 68 | 90 | $49,068 | $9,600 | 19.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 26 | 27 | $18,306 | $4,303 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $12,348 | $2,516 | 20.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 90 | 158 | $70,468 | $11,513 | 16.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 68 | $23,800 | $5,478 | 23.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 32 | 42 | $22,566 | $4,736 | 21.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 26 | 26 | $17,628 | $4,201 | 23.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $12,348 | $2,460 | 19.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 34 | 114 | $39,900 | $9,312 | 23.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 82 | 162 | $72,348 | $8,764 | 12.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 45 | 51 | $27,588 | $4,381 | 15.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 22 | 23 | $15,594 | $3,847 | 24.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 19 | 19 | $13,034 | $2,442 | 18.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 11 | 15 | $7,932 | $1,328 | 16.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 20 | 23 | $10,258 | $1,314 | 12.8% |
About Dr. Suzanne Kirby, MD
Dr. Suzanne Kirby, MD is a Hematology & Oncology healthcare provider based in Cary, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245305598.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Suzanne Kirby, MD has received a total of $4,034 in payments from pharmaceutical and medical device companies, with $102.84 received in 2024. These payments were reported across 20 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($2,400).
As a Medicare-enrolled provider, Kirby has provided services to 1,038 Medicare beneficiaries, totaling 1,785 services with total Medicare billing of $152,272. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Cary, NC
- Active Since 11/22/2006
- Last Updated 01/07/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1245305598
Products in Payments
- Rituxan (Biological) $3,501
- Optune (Device) $135.43
- KEYTRUDA (Biological) $121.12
- JAKAFI (Drug) $102.84
- Abraxane (Drug) $35.60
- TASIGNA (Drug) $22.32
- JADENU (Drug) $20.28
- NINLARO (Drug) $15.72
- DARZALEX (Biological) $15.12
- OPDIVO (Biological) $14.29
- Iclusig (Drug) $13.76
- AFINITOR (Drug) $13.49
- Nexavar (Drug) $12.26
- IMBRUVICA (Drug) $10.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cary
Dr. Amit Mehta, M.d, M.D
Hematology & Oncology — Payments: $4.1M
Hematology & Oncology $4.1M
Charles Eisenbeis, Md, MD
Hematology & Oncology — Payments: $131.63
Hematology & Oncology $131.63
Ms. Amanda Sherrod, Md, MD
Hematology & Oncology — Payments: $76.62
Hematology & Oncology $76.62
Maha Elkordy, M.d, M.D
Hematology & Oncology — Payments: $10.93
Hematology & Oncology $10.93
Paramjeet Singh, M.d, M.D
Hematology & Oncology
Hematology & Oncology
Sheila Shine, N.p, N.P
Hematology & Oncology
Hematology & Oncology